Amsterdam-headquartered health technology multinational Royal Philips has reached a comprehensive 288 million euro settlement with United States regulators regarding its prolonged sleep apnea device crisis. The finalized financial agreement removes a major cloud of legal and regulatory uncertainty that has heavily suppressed corporate valuation, allowing the company to refocus on expanding its data-driven medical hardware portfolio.